

Hepatitis B prevention in Singapore

Presented by

Dr. Chan Si Min

National University Hospital, Singapore



- This is a template that will be distributed among the participants of the groups discussions in the VHPB – Hanoi 2018 meeting on ‘Prevention and control of hepatitis B with combined vaccines and birth dose vaccination’
- The goal of this template is to get streamlined information, that can easily be compared, among participating countries.
- Please take this slides as a guideline, not as a fixed template. More information is always welcome but don’t exceed 10 slides
- Present only information for your specific country (no global neither Asian region information is requested)
- See also some additional notes in the note box of each slide



Hepatitis B Prevalence/Incidence in Singapore

	% Hep B (HBsAg) positives
General population incidence (2016)	0.8 per 100 000 population
General population prevalence (2010) 18-79 years old	3.6%

Table 5.1
Age-gender distribution and age-specific incidence rate of acute hepatitis B cases[^], 2016

Age group	Male	Female	Total	%	Incidence rate per 100,000 population*
0-4	0	0	0	0	0.0
5-14	0	0	0	0	0.0
15-24	3	0	3	6.5	0.4
25-34	8	5	13	28.3	1.0
35-44	14	2	16	34.8	1.6
45-54	5	2	7	15.2	0.9
55-64	4	1	5	10.9	0.8
65+	1	1	2	4.3	0.4
Total	35	11	46	100	0.8

[^]Excluded one foreigner seeking medical treatment in Singapore.
*Rates are based on 2016 estimated mid-year population.
(Source: Singapore Department of Statistics)

	% HBeAg +
Hep B pos pregnant women*	0.5%

*A total of 19,350 blood samples were screened at the KK Women's and Children's Hospital for HBsAg and HBeAg in 2016. Of these, 372 (1.9%) were HBsAg positive and 106 (0.5%) were HBeAg positive.



Vaccination coverage

Immunization coverage		
	Year (2007-2010) %	Year (2011-2016) %
BCG	98.9-99.5	98.6-99.6
DTP1 and DTP3	96.1-96.9	96.0-97.8
DTP booster1	88.3-91.0	89.7-91.4
HepB3	95.6-96.8	95.7-96.6
Hib3	85.6-92.0	81.6-96.3
Hib booster	81.0-89.6	77.9-89.8
IPV1 and IPV3	96.0-96.6	95.9-96.8
IPV booster1	86.6-90.6	89.5-91.2
MMR1	94.9-95.2	94.7-95.2
MMR2	92.4-96.0	86.2-91.6
PCV1 and PCV2	24.1-56.8	53.6-82.2
PCV3	18.5-23.2	41.4-77.7

*PCV data from 2009-2016

Vaccines:

BCG	Bacille Calmette Guérin vaccine	HepBb	HepB birth dose
DTP1	First dose of diphtheria toxoid, tetanus toxoid and pertussis vaccine	DTP3	Third dose of diphtheria toxoid, tetanus toxoid and pertussis vaccine
HepB3	Third dose of hepatitis B vaccine	Hib3	Third dose of Haemophilus influenzae type B vaccine
Pol3	Third dose of polio vaccine	PCV3	Third dose of Pneumococcal Conjugate
Rotac	Rotavirus last dose	Rcv1	First dose of Rubella Containing Vaccine
MCV1	First dose of Measles-containing vaccine	MCV2	Second dose of Measles-containing vaccine



Universal vaccination of hepatitis B in your country

Hepatitis B	Yes/no	Target <small>(who is vaccinate + age (if relevant))</small>	Since/period
Universal	Yes	All newborns	Sep 1987
Risk groups	Yes	Infants born to Hep B carrier mothers	Oct 1985
		Secondary school students to tertiary institutions, full time national servicemen	Jan 2001-2005



Hepatitis B prevention- Immunization

(combined/mono valent)

Available hepatitis vaccines	Disease	NAME (producer)	Target group
Monovalent	HepB	Engerix B 10mcg (GSK) Engerix B 20mcg (GSK)	
	HepB	Hbvaxpro 5mcg (MSD) Hbvaxpro 10mcg (MSD) Hbvaxpro 40mcg (MSD)	
Combined	HepB and HepA	Twinrix (GSK)	
	DTP/HiB/IPV and HepB	Infanrix Hexa (GSK) Hexaxim (Sanofi Pasteur)	

Issues with hepatitis/ Combined vaccination (what are the problems in your country with use of combined Hep B vaccination)

- Lack of data of Hexaxim use in preterm babies and Hep B carrier mothers
- Interchangeability data between the different combination vaccines

Opportunities (how do you think this issues can be solved)

- Recent introduction of Hexaxim as the main 6 in 1 combination vaccine in the public healthcare sector- to study use in preterm babies and Hep B carrier mothers



Extra information on birth dose(BD)vaccination

Singapore

	Yes/no	Since/period	Coverage
Birth dose vaccination in universal vaccination program	Yes	Sep 1987	95-96% (3 doses)

Issues with BD in your country

- Vaccine coverage data systematically collected only for Singapore nationals and permanent residents

Successes with BD in your country

- In general, well accepted with high coverage.

